Artículo
Potential use of peptides mimicking CRAC/CARC domains as antivirulence therapies to inhibit RTX toxins activities
Fecha de publicación:
11/2024
Editorial:
Open Exploration
Revista:
Exploration of Drug Science
e-ISSN:
2836-7677
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
In recent years, research efforts have increased to develop new therapeutics aimed at combating antibiotic resistant bacterial infections. These efforts focus on inhibiting the virulence factors bacteria secrete to proliferate. This review aims to highlight the advances in these antivirulence therapies, with a particular emphasis on those utilizing peptides to inhibit toxin activity. Specifically, we will review the mechanism of action of a group of toxins known as Repeat in ToXins (RTX) and the progress made regarding the use of peptides to inhibit their action. Notably, we will discuss the use of peptides mimicking either cholesterol recognition/interaction amino acid consensus (CRAC) or CARC motifs, which are similar to CRAC motifs but have the opposite orientation, to reduce their interaction with cholesterol in target cells. We will present results corresponding to the inhibition of three characteristic toxins of this group: HlyA from Escherichia coli, LtxA from Aggregatibacter actinomycetemcomitans, and CyaA from Bordetella pertussis. While these advances are very recent, they are promising for the development of new therapies. The advantage of thistype of therapy is that it reduces the selective pressure for the growth of resistant bacteria.
Palabras clave:
RTX toxins
,
antivirulence therapies
,
CRAC/CARC domains
,
HlyA of E. coli
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(INIBIOLP)
Articulos de INST.DE INVEST.BIOQUIMICAS DE LA PLATA
Articulos de INST.DE INVEST.BIOQUIMICAS DE LA PLATA
Citación
Herlax, Vanesa Silvana; Potential use of peptides mimicking CRAC/CARC domains as antivirulence therapies to inhibit RTX toxins activities; Open Exploration; Exploration of Drug Science; 11-2024; 836-850
Compartir
Altmétricas